Clinica BavieraXMAD:CBAV +0.71%100 Median PS Value is €35.14 as of Jun. 25, 2026, which is 100% below its 10-year median of 1.11. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €41.30 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 86 Medical Diagnostics & Research companies, Clinica Baviera ranks worse than 88.37% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Clinica Baviera's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €19.263. Clinica Baviera's 10-Year median PS Ratio is 1.8242. Therefore, the Median PS Value for today is €35.14.
As of today (2026-06-25), Clinica Baviera's share price is €56.60. Clinica Baviera's Median PS Value is €35.14. Therefore, Clinica Baviera's Price to Median PS Value for today is 1.61.
The historical rank and industry rank for Clinica Baviera's Median PS Value or its related term are showing as below:
XMAD:CBAV'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.84 Med: 1.11 Max: 1.61
Current: 1.61
During the past 13 years, the highest Price to Median PS Value of Clinica Baviera was 1.61. The lowest was 0.84. And the median was 1.11.
XMAD:CBAV's Price-to-Median-PS-Value is ranked worse than 88.37% of 86
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.87
vs XMAD:CBAV: 1.61
Clinica Baviera (XMAD:CBAV) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Clinica Baviera's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
56.60
/
35.14
=
1.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinica Baviera Median PS Value Related Terms
Clinica Baviera Median PS Value Historical Data
* Premium members only.
The historical data trend for Clinica Baviera's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:CBAV vs TMO, DHR, IDXX: Median PS Value Comparison
For the Diagnostics & Research subindustry, Clinica Baviera's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.8242.
Clinica Baviera's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €19.263.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinica Baviera (XMAD:CBAV) has a Median PS Value of €35.14 as of Jun. 25, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Clinica Baviera and its competitors. This is 3066% above median its historical median of 1.11. Over the past decade, Clinica Baviera's Median PS Value has ranged from 0.84 to 1.61. According to the industry distribution chart, Clinica Baviera ranks #76 out of 86 companies in the Medical Diagnostics & Research industry, placing it in the top 88.4%.
Is Clinica Baviera's Median PS Value too high?
Clinica Baviera's current Median PS Value of €35.14 is 3066% above median its 10-year median of 1.11. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 1.61. Based on the distribution chart, Clinica Baviera ranks #76 out of 86 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's Median PS Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #76 out of 86 companies for Median PS Value. This places Clinica Baviera in the lower half of its industry. The industry median Median PS Value is 0.87. Historically, Clinica Baviera's own Median PS Value has ranged from 0.84 to 1.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.87, based on 86 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Clinica Baviera and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinica Baviera's current Median PS Value is €35.14, which is 3066% above median its own 10-year median of 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.30, compared to a current price of €56.60 — trading 37% above its estimated fair value. The current Median PS Value is €35.14, which is 3066% above median its 10-year median of 1.11. Clinica Baviera's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current Median PS Value is €35.14 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €56.60 is trading 37% above its estimated GF Value™ of €41.30.
GuruFocus considers Clinica Baviera to be Significantly Overvalued.
Key valuation signals for XMAD:CBAV:
Median PS Value: €35.14 (3066% above median its 10-year median of 1.11)
GF Value™: €41.30 vs. price of €56.60 (37% above fair value)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
